LAB vs SPGI · rev $174.4M vs P/E 27, rev $15.34B
Standard Biotools Inc (LAB) versus S&P Global Inc (SPGI) — a side-by-side from cached financials, not a winner call.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
S&P Global Inc (SPGI) is a financial data & stock exchanges company listed on NYSE.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
Latest reported SPGI revenue for 2025-12-31 was $15.34B. Net income was $4.47B. Revenue was up 7.9% from 2024-12-31 to 2025-12-31. SPGI currently screens at market cap $127.50B and trailing P/E 27.2.
LAB currently screens at market cap $317.1M. SPGI currently screens at market cap $127.50B and trailing P/E 27.2.
Not investment advice. Open the LAB and SPGI stock pages for the full models.
Not investment advice.